Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Granuloma Annulare
Description
The talk on granuloma annulare (GA) presented comprehensive insights into its epidemiology, clinical presentation, pathogenesis, and treatment options. GA has an annual incidence of approximately 0.4%, predominantly affecting white women, especially in their 50s, with associations to systemic conditions like diabetes and dyslipidemia. Clinical manifestations range from localized to generalized lesions, which may appear as pink to brown annular plaques or papules. The diagnosis can be challenging due to overlapping features with other annular dermatoses. The speaker emphasized the importance of recognizing distinct characteristics of GA through tactile examination and visual cues, highlighting the role of dermal processes. The discussion included various treatment options, particularly noting the lack of FDA-approved medications and the reliance on off-label therapies. For localized GA, high-potency topical steroids are effective, while generalized cases may respond better to systemic treatments like hydroxychloroquine, TNF inhibitors, and potential oral JAK inhibitors, particularly in recalcitrant instances. A treatment algorithm was suggested, emphasizing a systematic approach that starts with less aggressive therapies before escalating as needed. The relevance of ongoing research into pathogenesis, suggesting a TH-1 mediated response, is crucial for understanding treatment mechanisms. The session concluded with an endorsement for the cyclical reconsideration of therapies as understanding of GA evolves.
View moreConclusions
- Granuloma annulare (GA) has an annual incidence of approximately 0.4%, translating to over 1 million cases annually in the US.
- GA primarily affects white women in their 5th decade of life, with a female to male ratio of about 3:1.
- There are notable associations between GA and systemic conditions such as diabetes, dyslipidemia, thyroid disease, and hematologic malignancies.
- Patients with generalized GA should undergo appropriate screenings for diabetes, lipids, thyroid function, and age-appropriate cancer screenings, especially if they are over 50 or exhibit atypical presentations.
- Drug-induced GA can occur, particularly with biologic medications that are generally used to treat GA, such as anti-TNF agents.
- Clinically, GA presents as heterogeneous lesions which can be localized or generalized, with 15-25% of cases being generalized.
- Histologically, GA is characterized by a distinct pattern involving palisading histiocytes and mucin deposition in the dermis.
- Pathogenesis research indicates that GA may involve a TH1-mediated immune response, with cytokines playing a significant role in the inflammatory process.
- The proposed treatment algorithm for generalized GA includes using hydroxychloroquine as first-line therapy, with options for adjunct therapies such as doxycycline and pentoxifylline.
- The treatment algorithm showed that approximately 88.9% of patients achieved a partial or complete response, with hydroxychloroquine being effective in around 56% of cases.
- For recalcitrant cases, TNF inhibitors have shown a 100% response rate, supporting their use in severe disease.
- Future treatment considerations may include Janus kinase (JAK) inhibitors, which have been shown to offer relief in difficult cases of GA.
- Barbieri JS, et al. JAMA Dermatol. 2021.
- Garate D, et al. JAAD. 2023.
- Durgin JS, et al. JAAD Case Rep. 2020
- Berk-Krauss et al. JAAD. 2024
- Grewal, et al. JAAD. 2017.
- Wang, et al. J Allergy Clin Immunol. 2021.